Loading clinical trials...
Loading clinical trials...
The goal of this clinical trial is to learn the dose-limiting toxicity of the new combined treatment with irinotecan liposomes (intravenous injection) and epirubicin (intravesical instillation) in ant...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
First Affiliated Hospital of Chongqing Medical University
NCT06770582 · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, and more
NCT04164082 · Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, and more
NCT05521698 · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
NCT07064863 · NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, and more
NCT05418309 · High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
The First Affiliated Hospital of Chongqing Medica University
Chongqing
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions